Prevention of Allergic Inflammation by a Novel Prostaglandin Receptor Antagonist, S-5751

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 298; no. 2; pp. 411 - 419
• Main Authors: Arimura, A, Yasui, K, Kishino, J, Asanuma, F, Hasegawa, H, Kakudo, S, Ohtani, M, Arita, H
• Format: Journal Article
• Language: English
• Published: United States American Society for Pharmacology and Experimental Therapeutics 01.08.2001
• Subjects: Animals; Blood Platelets - drug effects; Cell Membrane - drug effects; Cell Membrane - metabolism; Conjunctivitis - drug therapy; Conjunctivitis - pathology; Cyclic AMP - blood; Guinea Pigs; HL-60 Cells; Humans; Hypersensitivity - complications; Hypersensitivity - prevention & control; In Vitro Techniques; Inflammation - etiology; Inflammation - prevention & control; Ligands; Male; Prostaglandin Antagonists - pharmacology; Receptors, Prostaglandin - drug effects; Respiratory Tract Diseases - drug therapy; Respiratory Tract Diseases - pathology; Rhinitis, Allergic, Seasonal - drug therapy; Rhinitis, Allergic, Seasonal - pathology; Thiophenes - pharmacology
• ISSN: 0022-3565; 1521-0103

Prostaglandin (PG) D 2 , the major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, since no DP receptor antagonist has been developed as an antiallergic drug, the role of PGD 2 in the pathogenesis of allergic diseases remains uncertain. Here, we report the in vivo efficacy of our newly established DP receptor antagonist, S-5751 [(( Z )-7-[(1 R ,2 R ,3 S ,5 S )-2-(5-hydroxy benzo[ b ]thiophen-3-ylcarbonylamino)-10-norpinan-3-yl]hept-5- enoic acid)], using various allergic inflammation guinea pig models. In allergic rhinitis models, oral administration of S-5751 dramatically inhibited not only early nasal responses, as assessed by sneezing, mucosal plasma exudation, and nasal blockage, but also late responses such as mucosal plasma exudation and eosinophil infiltration. Even when S-5751 was administered after recovery from the early responses, these late phase responses were almost completely suppressed. In addition, S-5751 alleviated allergen-induced plasma exudation in the conjunctiva in an allergic conjunctivitis model and antigen-induced eosinophil infiltration into the lung in an asthma model. These findings provide evidence for the crucial role of PGD 2 as a mediator of allergic inflammation in guinea pigs and suggest that DP receptor antagonists may be useful in the treatment of allergic diseases triggered by mast cell activation.